These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22137560)

  • 1. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
    Tian Y; Zhang J; Yan S; Qiu L; Li Z
    Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
    J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
    Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
    Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
    Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
    Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
    Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
    Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
    Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
    Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
    Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
    Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC.
    Grimminger PP; Maus MK; Schneider PM; Metzger R; Hölscher AH; Sugita H; Danenberg PV; Alakus H; Brabender J
    Lung Cancer; 2012 Oct; 78(1):87-91. PubMed ID: 22884253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
    Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
    Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
    Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
    Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.